Abraham Ceesay - Jun 6, 2024 Form 3 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Chief Executive Officer, Director
Signature
/s/ Cheryl Gault, Attorney-in-Fact
Stock symbol
RAPP
Transactions as of
Jun 6, 2024
Transactions value $
$0
Form type
3
Date filed
6/6/2024, 06:49 PM
Previous filing
Oct 11, 2023
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RAPP Common Stock 626K Jun 6, 2024 Direct
holding RAPP Common Stock 81.7K Jun 6, 2024 By Ceesay Family Irrevocable Trust F1
holding RAPP Common Stock 81.7K Jun 6, 2024 By Dorothy Ceesay Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RAPP Stock Option (Right to Buy) Jun 6, 2024 Common Stock 264K $1.80 Direct F3
holding RAPP Stock Option (Right to Buy) Jun 6, 2024 Common Stock 254K $9.60 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2 Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3 25% of the shares underlying this option shall vest and become exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F4 25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney